Ankara Private IVF center, Ankara, Turkey.
Reprod Biomed Online. 2009 Oct;19(4):472-7. doi: 10.1016/j.rbmo.2009.04.001.
This study was designed to evaluate the effect of luteal-phase administration of single-dose gonadotrophin-releasing hormone (GnRH) agonist on pregnancy, implantation and live birth rates in patients who received GnRH antagonist for pituitary suppression. The study population consisted of 164 patients who underwent intracytoplasmic sperm injection (ICSI) after ovulation induction by gonadotrophins and GnRH antagonist for the prevention of a premature LH surge. For luteal-phase support, all the cases received intravaginal 600 mg micronized progesterone. In this prospective study, patients were randomly assigned to two groups. In one group, patients received an additional single dose of GnRH agonist (0.5 mg leuprolide acetate) subcutaneously on day 6 after ICSI, whereas the patients in the other group did not. Although the number of embryos transferred and the grade of the embryos were similar in the two groups, the patients in the luteal-phase agonist group had significantly higher rates of implantation and clinical pregnancy rates ( P < 0.05). When the two groups were compared, there were also statistically significant differences in multiple pregnancy and live birth rates ( P < 0.05). Administration of single-dose GnRH agonist as a luteal-phase support in ovarian stimulation-GnRH antagonist cycles in addition to standard luteal support seems to be effective in all cycle outcome parameters.
这项研究旨在评估黄体期给予单次剂量促性腺激素释放激素（GnRH）激动剂对接受 GnRH 拮抗剂进行垂体抑制的患者妊娠、着床和活产率的影响。研究人群包括 164 名接受促性腺激素和 GnRH 拮抗剂诱导排卵后进行胞浆内精子注射（ICSI）的患者，以预防过早的 LH 峰。黄体期支持时，所有患者均接受阴道内 600mg 微粒化黄体酮。在这项前瞻性研究中，患者被随机分为两组。一组患者在 ICSI 后第 6 天接受额外的单次 GnRH 激动剂（0.5mg 醋酸亮丙瑞林）皮下注射，而另一组患者则不接受。尽管两组患者的胚胎移植数量和胚胎等级相似，但黄体期激动剂组的着床率和临床妊娠率显著更高（P<0.05）。两组比较时，多胎妊娠和活产率也存在统计学差异（P<0.05）。在卵巢刺激-GnRH 拮抗剂周期中，除了标准黄体支持外，给予单次 GnRH 激动剂作为黄体期支持似乎对所有周期结局参数都有效。
